PE-22-28 results: what to expect and when
An experimental mood peptide studied in mice, with no human trials found.
Also called: PE 22-28, PE22-28, Mini-spadin, GVSWGLR.
Nootropic peptides · Shortened spadin analogue; experimental TREK-1 potassium-channel modulator · Evidence: Animal studies only.
Three PE-22-28 or mini-spadin papers studied mice or cells. Two studies of the longer peptide spadin give background; no human dosing study or registered trial was found.
Key studies
- PE-22-28 in mice and cells: PE-22-28 changed mouse behavior and cell-growth markers; human benefit remains untested. (source)
- Mini-spadin after experimental stroke: Mini-spadin affected recovery and mood-like behavior in stroke-injured mice. (source)
- Mini-spadin in insulin-making cells: Mini-spadin protected cultured insulin-making cells; this is not evidence for diabetes treatment in people. (source)
- Parent spadin discovery: Parent spadin linked TREK-1 inhibition to antidepressant-like effects in mice. (source)
- Parent spadin: assay-dependent effects: Parent spadin effects depended on channel activation and experimental conditions. (source)
Related to PE-22-28
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- Dihexa: An experimental memory compound with disputed animal research and no established human dose.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- Cerebrolysin: An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Drugs@FDA: FDA-Approved Drugs, US Food and Drug Administration
- Frequently Asked Questions About Suicide, National Institute of Mental Health
- Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study., Ashraf AR et al. · Journal of medical Internet research · 2024
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.